Additionally, LG has been found to decrease lipogenesis in NAFLD mice by modulating the PPAR signaling pathway, thereby reducing hepatic inflammation and enhancing intestinal barrier function. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.